
Afzal-Ur-Rahman Mohammed

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4891036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Profiling gene expression dynamics underpinning conventional testing approaches to better inform pre-clinical evaluation of an age appropriate spironolactone formulation. Pharmaceutical Development and Technology, 2021, 26, 101-109.	1.1	1
2	Novel, Fully Characterised Bovine Taste Bud Cells of Fungiform Papillae. Cells, 2021, 10, 2285.	1.8	2
3	Formulation and Bioequivalence Testing of Fixed-Dose Combination Orally Disintegrating Tablets for the Treatment of Tuberculosis in the Paediatric Population. Journal of Pharmaceutical Sciences, 2020, 109, 3105-3113.	1.6	4
4	Evaluation of anti-biofilm activity of acidic amino acids and synergy with ciprofloxacin on Staphylococcus aureus biofilms. Scientific Reports, 2020, 10, 9021.	1.6	52
5	Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets. Scientific Reports, 2019, 9, 12467.	1.6	13
6	Delivery of Poorly Soluble Drugs via Mesoporous Silica: Impact of Drug Overloading on Release and Thermal Profiles. Pharmaceutics, 2019, 11, 269.	2.0	39
7	High-throughput screening of excipients with a biological effect: a kinetic study on the effects of surfactants on efflux-mediated transport. Journal of Pharmacy and Pharmacology, 2019, 71, 889-897.	1.2	15
8	Understanding the compaction behaviour of low-substituted HPC: macro, micro, and nano-metric evaluations. Pharmaceutical Development and Technology, 2018, 23, 442-453.	1.1	5
9	Quality by Design (QbD) based process optimisation to develop functionalised particles with modified release properties using novel dry particle coating technique. PLoS ONE, 2018, 13, e0206651.	1.1	14
10	Current opinions and recommendations of paediatric healthcare professionals – The importance of tablets: Emerging orally disintegrating versus traditional tablets. PLoS ONE, 2018, 13, e0193292.	1.1	11
11	Dosage form preference consultation study in children and young adults: paving the way for patient-centred and patient-informed dosage form development. European Journal of Hospital Pharmacy, 2017, 24, 332-337.	0.5	17
12	Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100-55 from fast disintegrating tablets. International Journal of Pharmaceutics, 2017, 531, 80-89.	2.6	41
13	Microparticle surface layering through dry coating: impact of moisture content and process parameters on the properties of orally disintegrating tablets. Journal of Pharmacy and Pharmacology, 2017, 69, 807-822.	1.2	1
14	Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug Design, Development and Therapy, 2017, Volume11, 811-826.	2.0	16
15	Multiparticulate Systems for Paediatric Drug Delivery. Advances in Delivery Science and Technology, 2017, , 213-236.	0.4	1
16	An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug. PLoS ONE, 2017, 12, e0178772.	1.1	56
17	Design of Experiments to Study the Impact of Process Parameters on Droplet Size and Development of Non-Invasive Imaging Techniques in Tablet Coating. PLoS ONE, 2016, 11, e0157267.	1.1	14
18	Pre-formulation and systematic evaluation of amino acid assisted permeability of insulin across in vitro buccal cell layers. Scientific Reports, 2016, 6, 32498.	1.6	26

#	Article	IF	CITATIONS
19	Characterisation and surface-profiling techniques for composite particles produced by dry powder coating in pharmaceutical drug delivery. Drug Discovery Today, 2016, 21, 550-561.	3.2	8
20	A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol. Scientific Reports, 2015, 5, 16352.	1.6	12
21	A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 1-10.	2.0	30
22	Paediatric drug development of ramipril: reformulation, <i>in vitro</i> and <i>in vivo</i> evaluation. Journal of Drug Targeting, 2015, 23, 854-863.	2.1	3
23	A methodological evaluation and predictive in silico investigation into the multi-functionality of arginine in directly compressed tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 272-281.	2.0	0
24	Functionalised particles using dry powder coating in pharmaceutical drug delivery: promises and challenges. Expert Opinion on Drug Delivery, 2015, 12, 1867-1879.	2.4	23
25	Challenges and emerging solutions in the development of compressed orally disintegrating tablets. Expert Opinion on Drug Discovery, 2014, 9, 1109-1120.	2.5	25
26	A novel concentration dependent amino acid ion pair strategy to mediate drug permeation using indomethacin as a model insoluble drug. European Journal of Pharmaceutical Sciences, 2014, 62, 124-131.	1.9	19
27	Evidence-Based Nanoscopic and Molecular Framework for Excipient Functionality in Compressed Orally Disintegrating Tablets. PLoS ONE, 2014, 9, e101369.	1.1	13
28	Systematic Screening of Compressed ODT Excipients: Cellulosic Versus Non-Cellulosic. Current Drug Delivery, 2014, 11, 486-500.	0.8	12
29	Compressed orally disintegrating tablets: excipients evolution and formulation strategies. Expert Opinion on Drug Delivery, 2013, 10, 651-663.	2.4	57
30	Dissolution rate enhancement, in vitro evaluation and investigation of drug release kinetics of chloramphenicol and sulphamethoxazole solid dispersions. Drug Development and Industrial Pharmacy, 2013, 39, 704-715.	0.9	12
31	Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Therapeutic Delivery, 2013, 4, 395-413.	1.2	51
32	A systematic and mechanistic evaluation of aspartic acid as filler for directly compressed tablets containing trimethoprim and trimethoprim aspartate. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 468-476.	2.0	4
33	Preparation and Characterization of Amino Acids-Based Trimethoprim Salts. Pharmaceutics, 2012, 4, 179-196.	2.0	26
34	The impact of ageing on the barriers to drug delivery. Journal of Controlled Release, 2012, 161, 389-398.	4.8	42
35	Multi Stage Strategy to Reduce Friability of Directly Compressed Orally Disintegrating Tablets. Drug Delivery Letters, 2012, 2, 195-201.	0.2	2
36	Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 627-634.	2.0	31

#	Article	IF	CITATIONS
37	The Influence of Formulation and Manufacturing Process Parameters on the Characteristics of Lyophilized Orally Disintegrating Tablets. Pharmaceutics, 2011, 3, 440-457.	2.0	16
38	Use of Amino Acids as Counterions Improves the Solubility of the BCS II Model Drug, Indomethacin. Current Drug Delivery, 2011, 8, 363-372.	0.8	38
39	Systems biology approach to study permeability of paracetamol and its solid dispersion. International Journal of Pharmaceutics, 2011, 417, 272-279.	2.6	20
40	Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000. Journal of Pharmaceutical Sciences, 2011, 100, 4281-4294.	1.6	18
41	Genomic evaluation during permeability of indomethacin and its solid dispersion. Journal of Drug Targeting, 2011, 19, 615-623.	2.1	7
42	Effects of ball-milling on PLGA polymer and its implication on lansoprazole-loaded nanoparticles. Journal of Basic and Clinical Pharmacy, 2011, 2, 71-82.	9.3	4
43	Recent Patents and Trends in Orally Disintegrating Tablets. Recent Patents on Drug Delivery and Formulation, 2010, 4, 178-197.	2.1	22
44	Preparation, Optimisation and Characterisation of Lyophilised Rapid Disintegrating Tablets Based on Gelatin and Saccharide. Current Drug Delivery, 2010, 7, 65-75.	0.8	20
45	Investigation of Formulation and Process of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid Combination. Pharmaceutics, 2010, 2, 1-17.	2.0	13
46	Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 254-262.	2.0	32
47	Increased potential of a cationic liposome-based delivery system: Enhancing stability and sustained immunological activity in pre-clinical development. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 404-412.	2.0	30
48	The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 119-129.	2.0	73
49	Amino acids as cryoprotectants for liposomal delivery systems. European Journal of Pharmaceutical Sciences, 2007, 30, 406-413.	1.9	49